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Abstract 
 
A common observation in clinical studies dedicated to carotenoids is the huge interindividual 
variability in absorption and blood and tissue responses in these compounds. The recent 
discovery that several proteins are involved in carotenoid metabolism in humans has 
prompted a possible explanation for this phenomenon: genetic variants in genes encoding for 
these proteins may affect their expression or activity, and in turn carotenoid metabolism and 
carotenoid status. The proteins clearly identified so far are: the carotene oxygenases BCMO1 
(β,β-carotene-15,15’-monooxygenase) and BCDO2 (β,β-carotene-9,9’-oxygenase), which are 
involved in carotenoid cleavage, SR-BI (scavenger receptor class B type I), CD36 (Cluster 
Determinant 36)) and NPC1L1 (Niemann Pick C1-like 1), which are involved in carotenoid 
uptake by cells, and GSTP1 (glutathione S-transferase Pi 1) and HR-LBP (human retinal 
lutein-binding protein), which are involved in the transport of xanthophylls in the retina. 
Other proteins, such as ABCG5 (ATP-binding cassette sub-family G member 5) and the 
FABPs (fatty acid binding proteins) are also apparently involved, although firmer evidence is 
still required. A genome-wide association study, as well as several candidate gene association 
studies, have shown that groups of subjects bearing different alleles in single nucleotide 
polymorphisms located in or near several of the above-mentioned genes display different 
blood and/or tissue concentrations of carotenoids. Further studies are needed to identify all the 
proteins involved in carotenoid metabolism and assess whether other types of genetic 
variation, e.g. copy number variants and epigenetic modifications, can modulate carotenoid 
status. One potential application of such research could be personalized dietary guidelines for 
carotenoids according to individual genetic characteristics. 
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Introduction 
 
Carotenoids are lipid microconstituents found mainly in foods of plant origin. They can be 
divided into provitamin A and non-provitamin A carotenoids. The main provitamin A 
carotenoids are β-carotene, α-carotene and β-cryptoxanthin. These carotenoids can be 
considered as vitamin A, i.e. retinyl esters, when dietary preformed vitamin A fails to meet 
the body’s needs. The non-provitamin A carotenoids, the main ones being lutein, lycopene 
and zeaxanthin, are not considered as vitamins because their essentiality for humans is not yet 
proven. However, numerous studies have suggested that they can be beneficial for human 
health [1, 2], and some of them may play a specific biological role in humans, e.g. in lutein 
and eye biology [3–6]. 
Interest in the metabolism of carotenoids has increased in the last decade because of 
the associations between several degenerative diseases, e.g. cancers, cardio-vascular diseases, 
and eye diseases, and either the dietary intake of these molecules or their blood or tissue 
concentrations. In addition, clinical studies performed with carotenoids have systematically 
observed a huge variability in blood and, when measured, tissue response, i.e. variation in 
concentrations of dietary carotenoids. This has even led some researchers to divide subjects 
into low and high responders to carotenoids. It was further observed that the low or high 
responder phenotype was an intrinsic individual characteristic [7] and it was hypothesized that 
this was due to genetic characteristics of the individuals [7]. However, when this hypothesis 
was advanced, only BCMO1 (β,β-carotene-15,15’-monooxygenase) was known to participate 
in carotenoid metabolism and it was not possible to explain the interindividual variability by 
genetic variations for this enzyme only. In the following decade several proteins were found 
to be involved in the intestinal uptake, intracellular transport and cleavage of carotenoids. A 
reasonable hypothesis can thus be proposed: genetic variants in genes that encode these 
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proteins may affect expression or activity of these proteins and in turn carotenoid metabolism 
and carotenoid status. 
This review first presents proteins involved in carotenoid metabolism in humans. It 
then focuses on SNPs (single nucleotide polymorphisms) that have been associated with 
carotenoid status and examines other types of genetic variations that might affect carotenoid 
status. Lastly we discuss the potential implications of these genetic variations in dietary 
guidelines for carotenoids. 
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1. HUGE INTERINDIVIDUAL VARIABILITY IN BLOOD AND TISSUE RESPONSES TO DIETARY 
CAROTENOIDS 
 
A huge interindividual variability in blood and tissue concentrations of carotenoids is 
consistently observed in healthy subjects. Obviously, this variability is in part due to the 
variability in intake of these dietary microconstituents. However, most clinical studies 
dedicated to measuring blood and tissue responses to diets supplemented with carotenoids, or 
to meals enriched with carotenoids, have observed a huge interindividual variability in 
absorption efficiency of carotenoids and in blood and tissue responses to dietary carotenoids 
[7–12]. An example of this variability is shown in Figure 1. This has even led some 
researchers to assert that some subjects are “non-responders” to carotenoids [11, 13-15]. 
Although the term “non-responder” is inappropriate because all healthy subjects are 
apparently responders to dietary carotenoids, since no healthy subject without detectable 
carotenoids in their blood or tissue has ever been found, there is clearly a huge variability in 
blood and tissue response to dietary carotenoids in the healthy population. As hypothesized in 
Section 3 this effect is probably due to variations in genes that encode proteins involved in 
carotenoid absorption and metabolism. 
 
2. PROTEINS DIRECTLY OR INDIRECTLY INVOLVED IN CAROTENOID METABOLISM 
 
Until recently it was assumed that carotenoids, being fat-soluble, simply followed lipids from 
the lipid droplets present in the gastro-intestinal lumen during digestion [16-18] to the 
intracellular lipid droplets where they are stored [19-21]. More precisely, it was assumed that 
they were first transferred from the food matrix, where they were embedded in the fat phase 
of the meal, and then transferred to mixed micelles during triglyceride lipolysis by pancreatic 
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lipase, before being absorbed by passive diffusion, incorporated in chylomicrons and 
distributed to tissues together with triglycerides and cholesterol. However, the reality is more 
complex because several proteins are involved, or are suspected of being involved, at different 
stages in this pathway. First, it is assumed that a digestive enzyme is involved in the 
hydrolysis of the carotenoids that are esterified. Second, it has been suggested that as 
observed for cholesterol, apical membrane proteins of the enterocyte are involved in the 
uptake of carotenoids. Finally, proteins are thought to be involved in the intracellular transport 
of carotenoids across the water environment of the cells, etc. Below we present a state-of-the-
art review concerning the proteins known so far to be involved in carotenoid metabolism in 
humans. 
 
2.1 CANDIDATE PROTEINS FOR HYDROLYSIS OF CAROTENOID ESTERS IN THE INTESTINAL LUMEN 
Although most dietary carotenoids are non-esterified, some carotenoids, e.g. xanthophylls 
present in supplements, can be esterified. Like other lipids it is assumed that only the free 
forms of carotenoids can be absorbed by the enterocyte. Thus it is assumed that an enzyme in 
the gastro-intestinal lumen and/or in the brush border of the enterocyte is responsible for the 
hydrolysis of carotenoid esters. Several candidates can be proposed. The first candidate, in 
order of appearance in the gastro-intestinal tract, is gastric lipase, which can hydrolyse up to 
17.5% of the triacyglycerols [22]. However, no data are available on the ability of this lipase 
to hydrolyse carotenoid esters. A second candidate could be pancreatic lipases, pancreatic 
lipase and pancreatic lipase-related protein 2, which are able to hydrolyse retinyl-palmitate 
[23]. Unfortunately, here again there are no available data on the ability of these lipases to 
hydrolyse carotenoid esters. The third and principal candidate is obviously cholesterol ester 
hydrolase [24-27], because it has a broad substrate specificity and because it is known to be 
involved in the hydrolysis of zeaxanthin esters in vitro [28]. However, we note that in vivo 
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studies using knock-out mice [29, 30] to confirm the involvement of this enzyme on 
tocopherol ester hydrolysis in vitro [24-27], have failed to confirm its involvement in its 
hydrolysis in vivo. A last candidate could be a brush border esterase, but again no data are 
available on this possibility. To conclude, several digestive enzymes could be involved in 
carotenoid ester hydrolysis in the human upper gastro-intestinal tract, but no such enzyme has 
yet been firmly identified.  
 
2.2 PROTEINS INVOLVED IN UPTAKE AND SECRETION OF CAROTENOIDS BY CELLS 
The first cell that makes contact with dietary carotenoids is obviously the enterocyte. Most of 
the studies dedicated to understanding mechanisms by which carotenoids are taken up and 
secreted by cells have been performed with intestinal cells or tissues. The first study was 
performed by the group of Hollander in the 1970s. This group, using rat everted intestinal 
sacs, concluded that absorption of β-carotene, and by extension absorption of all the 
carotenoids, was passive [31]. Although well conducted, this study was obviously limited by 
the technology available at that time. New studies performed during the last decade by several 
independent research teams have shown that the mechanism of absorption is actually more 
complex than was previously assumed: passive diffusion probably occurs at high, 
pharmacological concentrations of carotenoids, while a protein-mediated transport takes place 
at dietary doses. 
Available data suggest that there is no specific protein involved in uptake/efflux of 
carotenoid by cells. Recent studies suggest that it is lipid transporters – and especially 
cholesterol transporters – that are mainly involved in carotenoid uptake/efflux by cells. 
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2.2.1 The scavenger receptor class B type I (SR-BI) 
The first lipid transporter involved in carotenoid uptake is SR-BI. This lipid transporter is a 
single-chain trans-membrane glycoprotein of 80 kDa. SR-BI is found in various cell types 
including liver, testis, ovaries and macrophages [32], as well as on the brush border 
membrane of the enterocyte from the duodenum to the colon [33]. Its main ligands are HDL 
(high density lipoproteins), but also LDL (low density lipoproteins) and VLDL (very low 
density lipoproteins), anionic phospholipids and apoptotic cells [32]. SR-BI is able to 
facilitate the selective entry into the cell compartment of esterified cholesterol recovered in 
HDL [34]. At the intestinal level, it was first shown that SR-BI facilitated the uptake of free 
cholesterol, but also of esterified cholesterol, phospholipids and triacylglycerol hydrolysis 
products, thus displaying a broad ligand specificity [35, 36]. In 2005 SR-BI was identified for 
the first time as playing a role in the uptake of the carotenoid lutein at the intestinal level 
using Caco-2 cells [37], and this result was rapidly extended to other carotenoids, such as -
carotene [38], zeaxanthin [39] and lycopene [40], and to other cell types. SR-BI has also been 
shown to be involved in carotenoid uptake by retina pigment eptithelium [39], and it has been 
suggested that it is involved in the preferential uptake of xanthophylls by the macula [39]. The 
fact that SR-BI is important for carotenoid metabolism is supported by a recent study showing 
that its expression is modulated by provitamin A carotenoids. More precisely, by using both 
mouse models and human cell lines, it has been shown that carotenoid absorption by SR-BI is 
subject to control by retinoid signalling. Retinoic acid induces the expression of the intestinal 
transcription factor ISX, which represses the expression of both SR-BI and BCMO1. BCMO1 
acts downstream of SR-BI and converts absorbed beta-carotene into the retinoic acid 
precursor, retinaldehyde [41]. Thus there is a diet-responsive regulatory network that controls 
SR-BI mediated carotenoid absorption by a negative feedback regulation. 
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The role of SR-BI is not limited to the uptake of lipid molecules. It has been observed 
to function in both directions in the intestine [42] and in other tissues [34]. Concerning lipid 
micronutrients, it has been shown that SR-BI is able to efflux both vitamin E [43] and vitamin 
D [44] from Caco-2 cells. It may therefore be involved in the efflux of carotenoids from the 
enterocyte to the intestinal lumen, which may explain in part the very low absorption 
efficiency of these compounds, as also in the efflux of carotenoids from other tissues. 
Unfortunately, no data are available on the possible involvement of SR-BI in carotenoid 
efflux in any cell type. 
2.2.2 Cluster Determinant 36 (CD36) 
Another scavenger receptor apparently involved in carotenoid uptake by cells is FAT (fatty 
acid translocase), also known as CD36 in humans. This trans-membrane glycoprotein of 
90 kDa is mainly expressed in epithelial cells, adipocytes, platelets and macrophages [32], but 
it is also expressed in the duodenum and the jejunum [33]. As SR-BI, it can interact with a 
broad variety of ligands [32]. CD36 was first shown to be involved in -carotene uptake by 
cells using transfected COS-7 cells and mouse brush border membrane vesicles [38]. This 
involvement in carotenoid uptake by cells was confirmed recently in mouse 3T3-L1 
adipocytes and in mouse adipose tissue cultures [45].  
2.2.3 Niemann Pick C1-like 1 (NPC1L1) 
NPC1L1 is a 135 kDa protein widely expressed in human tissues, especially in the 
liver and the plasma membrane of the intestinal cell [46-50]. It is the main cholesterol and 
phytosterol transporter in the intestine [51]. NPC1L1 has been shown to be involved in both 
-tocopherol [52] and -tocotrienol [53] intestinal absorption using Caco-2 cells and in situ 
perfusions in rats. Results are less clearcut regarding carotenoids: in a first study [54], 
ezetimibe, a drug used to diminish dietary cholesterol absorption and that inhibits NPC1L1, 
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significantly inhibited the uptake of several carotenoids in Caco-2 cells. Conversely, in a 
second study that focused on lycopene [40], neither ezetimibe nor blocking antibody directed 
against NPC1L1 impaired its absorption in Caco-2. Further experiments are thus required to 
thoroughly assess the role of NPC1L1 in carotenoid metabolism. 
2.2.4 The ABC transporters 
The ABC transporters are a superfamily of transmembrane proteins able to transport a 
wide variety of substrates including drugs, lipids, bile salts, amino acids, peptides, proteins 
and oses. Most of these transporters are efflux proteins [55] that need ATP hydrolysis by two 
sites of ligation to ATP [56, 57]. In particular, the ABCG5/G8 heterodimer is critical in sterol 
homeostasis. The complex ABCG5/G8 acts as an efflux pump in the enterocyte, where it 
limits mainly phytosterol absorption. Interestingly, one study suggested a role of ABCG5 
(ATP-binding cassette sub-family G member 5) in lutein metabolism [58]. However, it was an 
association study that showed only an association (near-significant) between a genetic variant 
in ABCG5 and plasma lutein concentration. Dedicated studies are therefore required to assess 
the possible involvement of ABC transporters in carotenoid metabolism. 
 
In conclusion, it appears that several lipid transporters are involved in uptake/efflux of 
carotenoids by the intestinal cell (Figure 2) as well as by other cells (Table 1). However, the 
relative contribution of these transporters to the net uptake/efflux of each carotenoid species 
in different tissues is not known. In addition, it is likely that not all the transporters involved, 
peculiarly the ABC transporters, have yet been identified.  
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2.3 PROTEINS INVOLVED IN INTRACELLULAR TRANSPORT OF CAROTENOIDS 
The intracellular transport of carotenoids is not well known. It is assumed that being 
insoluble in water, these compounds require either intracellular proteins to cross the water 
compartments of the cells, or incorporation into intracellular membranes, to be transported 
within the cells. 
2.3.1 Carotenoid-binding proteins  
Two xanthophyll-binding proteins have been described in human retina: GSTP1 
(glutathione S-transferase Pi 1) [59], which binds zeaxanthin and (3R,3'S-meso)-zeaxanthin, 
and HR-LBP (human retinal lutein-binding protein), which binds lutein [60]. Apparently no-
one has tested whether these proteins are able to bind other carotenoids, e.g. β-carotene and 
lycopene, but these proteins, or proteins of the same family, are good candidates for 
intracellular transport of carotenoids in other tissues. 
2.3.1 Fatty acid-binding proteins (FABPs)  
The hypothesis that FABPs can participate in the intracellular transport of carotenoids 
comes from Hollander’s group. This team suggested, from results showing interactions 
between a fat soluble vitamin (phylloquinone) and linoleic acid, that a FABP might also be a 
carrier for fat-soluble micronutrients [61]. The fact that FABPs are able to bind different 
hydrophobic molecules [62, 63] supports this hypothesis. Two main fatty acid-binding 
proteins are found in human tissues: intestinal FABP, mainly recovered in the intestine, and 
liver FABP, recovered in the liver but also in other tissues. It is hypothesized that FABPs 
allow a specific intracellular trafficking of their ligands to their respective metabolic fates. 
Although dedicated studies need to be performed to verify whether intestinal and/or liver 
FABP are involved in intracellular transport of carotenoids, the fact that in a genetic 
association study, a genetic variant in intestinal FABP was associated with fasting plasma 
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lycopene concentrations [64] can be considered as a first argument that FABPs may be 
involved in the intracellular transport of some carotenoids. 
 
2.4 PROTEINS INVOLVED IN CAROTENOID CLEAVAGE 
The requirements for vitamin A can be satisfied either by animal foods containing 
preformed vitamin A, i.e. retinyl esters, or by plant foods containing provitamin A 
carotenoids. In humans, two different carotene oxygenases are involved in carotenoid 
cleavage: BCMO1 and BCDO2 (β,β-carotene-9,9’-oxygenase) [65]. BCMO1 is responsible 
for the symmetric cleavage [66, 67], while BCDO2 is responsible for the asymmetric 
cleavage. Immunohistochemical analysis revealed that BCMO1 was expressed in epithelial 
cells and in a variety of human tissues [68]. It is now assumed that it is the main enzyme 
responsible for vitamin A synthesis both in the intestine and the liver, and also for vitamin A 
synthesis in different tissues when local concentrations in vitamin A are insufficient. The 
biological role of BCDO2 has been unravelled recently [69]: it was shown in BCDO2-
deficient mice and in human cell cultures that BCDO2 was located in the mitochondria and 
that its main role was apparently to degrade carotenoids to protect mitochondria from 
carotenoid-induced dysfunctions. Interestingly, carotenoid homeostasis was impaired in 
BCDO2-deficient mice, leading to accumulation of carotenoids in several tissues. 
 
2.5 PROTEINS INVOLVED IN LIPOPROTEIN METABOLISM 
Because carotenoids are transported by blood lipoproteins [70], it has been hypothesized 
that genes involved in lipoprotein metabolism, e.g. genes that encode for apolipoproteins or 
for endothelial lipases, may indirectly affect blood concentrations of carotenoids by 
modulating the number, and/or the lipid composition, of the vehicles that transport 
carotenoids in the blood. This hypothesis is supported by several association studies showing 
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that blood carotenoid concentrations were significantly different in groups of subjects who 
bore different genetic variants in apolipoprotein A-IV [71], apolipoprotein B [71], 
apolipoprotein E [72], hepatic lipase [64] and lipoprotein lipase [73].  
 
In conclusion, it appears that several proteins are involved at numerous steps in carotenoid 
metabolism (Table 1). Some are specific, e.g. BCMO1, others are non-specific, 
e.g. cholesterol transporters, and still others are indirectly involved, e.g. apolipoproteins. The 
metabolism of carotenoids within the human body is therefore more complex than previously 
thought, i.e. a simple distribution of carotenoids within the lipid compartments of the body 
depending on the solubility of carotenoids in the different lipid phases. Several proteins are 
clearly involved in blood and tissue concentrations of carotenoids. 
 
3. HYPOTHESIS CONCERNING THE MODULATION OF CAROTENOID STATUS VIA GENETIC 
MODULATION OF EXPRESSION OR ACTIVITY OF PROTEINS INVOLVED IN CAROTENOID 
METABOLISM 
 
The fact that proteins are involved in cellular uptake, intracellular transport and cleavage of 
carotenoids raises the question of the consequences of modulations in the expression or 
activity of these proteins on blood and tissue concentrations of these compounds. The 
expression and activity of proteins can be modulated by several factors, including genetic 
ones. Genetic variations in or near genes that encode proteins may affect protein expression, 
e.g. a genetic variation that affects the binding of a transcription factor in the promoter region 
of a gene, or protein activity, e.g. a genetic variation that leads to a functional modification in 
the amino acid sequence of the protein, and in turn the ability of these proteins to accurately 
perform their function in the metabolism. Concerning carotenoids, it can be hypothesized that 
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genetic variations in genes that encode proteins involved in uptake, transport, and cleavage of 
these compounds will affect their absorption efficiency (Figure 3) as well as their blood and 
tissue concentrations. This hypothesis is supported by several studies showing associations 
between genetic variants in genes involved, or suspected to be involved, in carotenoid 
metabolism and blood and tissue concentrations of carotenoids. 
 
4. MUTATIONS AFFECTING CAROTENOID STATUS 
 
Very high skin concentrations of carotenoids cause carotenodermia. Carotenodermia is 
usually due to very high intake of carotenoids, such as in people, e.g. infants, eating large 
amounts of carrots or carrot-derived products. Yet cases of carotenodermia and/or 
hypercarotenemia have also been reported in which subjects had normal carotenoid intakes. It 
was hypothesized that these subjects had an impairment in the conversion of carotenoids to 
retinal by BCMO1 [74–77]. In support of this hypothesis a mutation that explains a case of 
metabolic carotenodermia has been identified recently [78]. The mutation led to the 
replacement of a threonine with a methionine, resulting in a 90% reduction of BCMO1 
activity. The hypercarotenemia was explained by the fact that BCMO1, which is saturated 
during normal dietary conditions, cleaved less dietary carotenoids than usual, leading to 
higher blood concentrations of carotenoids.  
 
5. MAIN SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) AFFECTING CAROTENOID STATUS 
 
GWAS (genome-wide association study) is today the most popular approach for identifying 
genetic variants and thus genes associated with phenotypes. In this approach, the frequency of 
genetic variants (often involving hundreds of thousands of SNPs studied simultaneously) is 
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investigated in large numbers of subjects (again often using DNA from thousands of 
subjects). There is only one GWAS study dedicated to identifing the main genetic variants 
associated with blood concentration of carotenoids [79]. This study, which was performed in a 
cohort of Italian and replicated with two US cohorts, showed that an SNP near the BCMO1 
gene, rs6564851, was significantly associated with plasma concentration of several 
carotenoids [12]. More precisely, the G allele at this SNP was simultaneously associated with 
higher concentrations of α and β-carotene and with lower concentrations of lycopene, lutein 
and zeaxanthin. This result confirms the key role of this enzyme in the metabolism of 
provitamin A carotenoids and shows that it is also involved, by an unknown mechanism, in 
the blood status of non-provitamin A carotenoids. We note that the association between lutein 
and BCMO1 genetic variants was also found in another study [80]. Although closely 
associated it was calculated that rs6564851 explained 1.9% of the variance in plasma β-
carotene concentration [79]. Thus other genetic variations, which could be the SNPs identified 
in candidate gene association studies (see Section 6), are probably involved. It is likely that 
the genetic variance involves several genetic variants with very small effects that cannot be 
detected in GWAS studies. The problem with GWAS is that to avoid false positive 
associations, it requires a dramatically low p-value threshold (p < 5 ×10
−7
) and so weaker 
associations have not yet been reported.  
 
6. OTHER SNPS AFFECTING CAROTENOID STATUS IDENTIFIED BY CANDIDATE GENE 
ASSOCIATION STUDIES 
 
Several candidate gene association studies have been performed in the past five years to 
assess whether SNPs in genes suspected to modulate carotenoid metabolism directly or 
indirectly can affect blood or tissue concentrations of carotenoids. The results of these studies 
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are summarized in Table 2. In summary, these studies have confirmed the key role of genetic 
variants in BCMO1 on carotenoid status that was observed in the GWAS study on carotenoid 
status [79] (see previous section). They have also found that, as expected, genetic variants in 
proteins shown to be involved in carotenoid metabolism in cell studies, e.g. SR-BI and CD36, 
apparently affect carotenoid status. Finally, they have potentially identified other 
genes/proteins involved in carotenoid status, e.g. apolipoproteins, ABCG5, liver FABP, 
although the role of these genes/proteins and the effect of their genetic variants on carotenoid 
metabolism need to be confirmed in dedicated molecular/functional studies. 
 
7. OTHER TYPES OF GENETIC VARIATION THAT MIGHT AFFECT CAROTENOID STATUS 
 
It is likely that the genetic component of interindividual variability in carotenoid status is due 
to the sum of effects due to variants in numerous genes. Other genetic and epigenetic 
variations may also contribute to interindividual variability in carotenoid status. Another 
genetic variation that occurs widely in the human genome is copy number variants. To date, 
there are no published studies of copy number variants and carotenoid status, but it is 
reasonable to expect such variants to be responsible for inter-individual variation in the 
activities of proteins involved in carotenoid metabolism. It is now assumed that epigenetic 
modifications of DNA, i.e. DNA methylation patterns (CpG sites), acetylation ubiquitination 
of histones, and very small (non-coding) RNAs (miRNA), play a major role in controlling 
gene expression. Given that miRNA regulate expression of about one third of all protein-
encoding genes across all cellular processes investigated [81], there is a high likelihood that 
they can play a role in carotenoid metabolism and thus in carotenoid status. In common with 
other regions of the genome, the domains encoding miRNA also contain SNPs [82], which 
adds a further layer of genetic complexity. 
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8. POTENTIAL IMPLICATIONS OF GENETIC VARIATIONS IN DIETARY GUIDELINES FOR 
CAROTENOIDS 
 
The fact that genetic variations can affect absorption efficiency of carotenoids and the 
conversion of provitamin A carotenoids in vitamin A raises two opposing questions: “Do 
subjects with low responder genotypes need a higher dietary intake of carotenoids to enjoy the 
beneficial effects of some carotenoids on health?”, and conversely, “Do subjects with high 
responder genotypes need to avoid high intake of some carotenoids because of the potential 
toxic effects of some carotenoids [83]?”. These questions may also be very relevant with 
regard to the fight against vitamin A deficiency in developing countries. If genetic variants do 
affect either absorption efficiency of provitamin A carotenoids, or their conversion into 
vitamin A, then it may be important to know whether a large proportion of persons in 
populations at risk of vitamin A deficiency, e.g. populations in some developing countries, 
bear genetic variants that lead to lower provitamin A activity of carotenoids. In that case it 
would be better to supplement these populations with preformed vitamin A rather than with 
provitamin A carotenoids. 
 
CONCLUSIONS 
 
Available data support the hypothesis that genetic variation is a key factor explaining the huge 
interindividual variability in carotenoid status. However, much work is still needed to identify 
all the proteins and genetic variants involved. In addition, such research will probably need to 
encompass both copy number variants and epigenetic variants. Because a key step of 
carotenoid status is their absorption efficiency, and because this first step is especially 
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variable, it is suggested that dedicated studies should be performed to identify genetic 
variations explaining this variability. The effect of genetic variants on plasma and tissue 
concentrations of carotenoids may affect the ability of carotenoids to prevent some diseases 
(e.g. cardiovascular diseases and cancers). Finally, because several carotenoids are apparently 
beneficial for health at low, dietary doses and can be hazardous at higher, pharmacological 
doses, we can envisage adapting recommended dietary intake of carotenoids, or doses of 
carotenoids incorporated in functional foods/supplements, to population groups carrying 
genetic variants known to affect carotenoid status. 
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Tables 
 
Table 1. Proteins involved in carotenoid metabolism
a
 
 
 
Intestine Liver Other tissues 
-carotene 
SR-BI [38] 
CD36 [38] 
NPC1L1 [54] 
BCMO1  
BCDO2 
BCMO1 
BCDO2
b
 
SR-BI (retinal pigment 
epithelial cells) [39]. 
BCDO2 
Lutein  
SR-BI [37] 
NPC1L1 [54] 
BCDO2 
BCDO2 CD36 (adipose tissue) 
[45] 
BCDO2 
Lycopene 
SR-BI [40] 
NPC1L1
c
 [54] 
BCDO2 
BCDO2 CD36 (adipose tissue) 
[45] 
BCDO2 
Other 
carotenoids 
Carboxyl ester lipase & 
zeaxanthin esters [28] 
NPC1L1
d
 [54] 
BCDO2 
BCDO2 SR-BI & zeaxanthin 
(retinal pigment 
epithelial cells) [39]. 
GSTP1 & zeaxanthin 
(macula) [59] 
HR-LBP & lutein (retina) 
[60] 
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BCDO2 
 
a
 proteins shown to be involved in carotenoid metabolism in cell studies. This table does not 
show proteins that have been associated only with blood or tissue concentrations of 
carotenoids. 
b
 BCDO2 has been recently described as a mitochondial enzyme with a broad substrate 
specificity [69]. It therefore appears throughout the table, although direct evidence of its 
involvement for carotenoid cleavage in each tissue is not available. 
c
 not confirmed in another study [40]. 
d
 involvement found for α-carotene, β-cryptoxanthin and zeaxanthin. 
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Table 2. Genetic variants (SNPs) that have been associated with carotenoid status in 
candidate gene association studies
a
 
 
Genes Genetic variants 
associated
b
 
Genotypes or 
alleles associated 
with lower 
concentrations of 
carotenoids
c
 
Carotenoids 
associated 
References 
ABCG5 Q640E G allele
d
 lutein [58] 
apo B 
apo B-516 
apo B-516 
C allele 
C allele
e
 
lycopene 
β-carotene 
[71] 
apo A-IV apo A-IV-Ser347 TT lycopene [71] 
apoE 
apo E2, E3, E4 E3/2 (vs E3/3) 
E3/2 (vs E3/3) 
lycopene 
α-carotene 
[72] 
BCDO2 
W80X 
 
c.196C>T 
G allele 
 
T allele 
β-carotene 
 
likely β-carotenef 
[84] 
[85] 
BCMO1 
rs6564851
g
 
 
R267S+A379V 
 
rs7501331 
rs7501331 
G allele
h
 
 
379A 
 
TT 
CT 
lycopene, lutein 
and zeaxanthin 
β-carotene 
 
lutein 
lutein
i
 
[79] 
[86] 
[80] 
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CD36 
rs1761667 
rs13230419 
A allele
 
CC 
lutein
9
 
lutein 
[80] 
HL 
HL C-480T TT
j
 
C allele
e
 
α-carotene 
β-carotene 
[64] 
FABP2 (intestinal 
FABP) 
IFABP-Thr GG
j
 lycopene [64] 
LPL 
S447X X447/X447 vs 
S447/S447 
β-carotene, α-
carotene and β-
cryptoxanthin 
[73] 
SCARB1 
SR-BI intron 5 
SR-BI intron 5 
SR-BI exon 1 
C allele 
C allele 
GG 
α-carotene 
β-carotene 
β-cryptoxanthin 
[71] 
 
a
 all data were obtained in humans except those of BCDO2 that were obtained in cattle and in 
sheep. 
b
 annotations as found in the publications. 
c
 associated with lower blood (plasma or serum) concentration of carotenoids when not 
specified. 
d
 near-significant (p = 0.08). 
e
 significant only in men. 
f
 associated with yellow fat phenotype, assumed to be related to β-carotene concentration. 
g
 near the BCMO1gene (identified in a GWAS study). 
h
 allele simultaneously associated with higher β-carotene and α-carotene concentrations. 
i
 associated with macular pigment optical density (assumed to reflect concentration of 
lutein/zeaxanthin in the macula). 
24 
 
j
 significant only in women. 
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Figure legends 
 
Figure 1. Interindividual variability in absorption efficiency of carotenoids. Example of 
lycopene. 
Interindividual variability in absorption efficiency of lycopene as evaluated by measuring 
postprandial chylomicron lycopene concentrations after intake of a lycopene-rich test meal. 
The same test meal was ingested by 39 healthy male adults. It contained 50 g fat and 100 g 
tomato purée as a source of lycopene (unpublished data from a clinical study funded by the 
FP6 Integrated European project “Lycocard”, No. 016213). Bold curve: mean chylomicron 
lycopene concentrations of the 39 subjects. Dashed curves: curves of the lowest responder 
(lowest area under the curve (AUC)) and the highest responder (highest AUC). The ratio 
between the AUC of the highest responder and that of the lowest responder was about 20. 
 
Figure 2. Proteins involved in carotenoid transport across the human enterocyte. 
Carotenoids are captured from mixed micelles by apical membrane transporters (SR-BI, 
CD36 and NPC1L1). A fraction of carotenoids might then be effluxed back to the intestinal 
lumen via apical membrane transporters (SR-BI and possibly ABCG5/G8). Another fraction 
of carotenoids is transported to the site where they are incorporated in chylomicrons. A 
fraction of provitamin A carotenoids, e.g. β-carotene, α-carotene, and β-cryptoxanthin, is 
transported to the site where they are cleaved into retinal by BCMO1. A fraction of non-
provitamin A carotenoids, e.g. lutein, zeaxanthin and lycopene, is possibly transported to 
mitochondria, where they are cleaved into apocarotenals by BCDO2. It is hypothesized that 
one or pore proteins are involved in intracellular transport of carotenoids, although they have 
not yet been identified. Good candidates are the FABPs. Non-metabolized carotenoids and 
retinyl esters, which originate from carotenoid cleavage by BCMO1 and subsequent 
metabolism by vitamin A enzymes, are secreted in the lymph in chylomicrons, while it is 
hypothesized that polar carotenoid metabolites are secreted in the portal route. 
36 
 
 
Figure 3. Interindividual variability of absorption efficiency of carotenoids as explained by 
genetic variation in proteins involved in transport and metabolism of carotenoids in the 
enterocyte. 
Ap: apical membrane transporter of carotenoids (e.g. SR-BI). Int: intracellular transporter of 
carotenoids (e.g. FABP). Cleav: enzyme involved in cleavage of carotenoids (e.g. BCMO1). 
A white symbol indicates that the protein works with maximal efficiency. A black symbol 
indicates that a genetic variation (e.g. an SNP) leads to an impaired expression or activity of 
the protein. A grey transporter indicates that a genetic variation leads to an intermediate 
expression or activity of the protein. The hypothesis is as follows: when most proteins 
involved in the metabolism of a carotenoid are efficient, subjects absorb the carotenoid very 
well: these subjects are called “high responders”. When most of the proteins involved in the 
metabolism of a carotenoid are inefficient, subjects absorb the carotenoid very poorly: these 
are called “low responders”. When some proteins are efficient and some are inefficient, the 
subjects absorb carotenoids with an intermediate efficiency; these are called “medium 
responders”. This hypothesis explains the Gaussian response to β-carotene described in a 
clinical study [7]. 
